PURPOSE: To determine the group II phospholipase A2 (PLA2) content of tears in patients with senile cataract or primary open-angle glaucoma (POAG) and to compare it with the PLA2 content of tears in age-matched healthy controls. METHODS: The PLA2 concentration of tears was measured with time-resolved fluoroimmunoassay in 21 patients with senile cataract, 23 patients with POAG and in 40 healthy controls. RESULTS: The PLA2 content of tears was 38.3+/-30.1 microg/ml in patients with senile cataract, 32.1+/-22.3 microg/ml in patients with POAG, and 36.6+/-31.1 microg/ml in healthy controls. There were no significant differences between the patient and the control groups. CONCLUSIONS: We conclude that neither senile cataract nor POAG has any effect on the PLA2 content of tears.
PURPOSE: To determine the group II phospholipase A2 (PLA2) content of tears in patients with senile cataract or primary open-angle glaucoma (POAG) and to compare it with the PLA2 content of tears in age-matched healthy controls. METHODS: The PLA2 concentration of tears was measured with time-resolved fluoroimmunoassay in 21 patients with senile cataract, 23 patients with POAG and in 40 healthy controls. RESULTS: The PLA2 content of tears was 38.3+/-30.1 microg/ml in patients with senile cataract, 32.1+/-22.3 microg/ml in patients with POAG, and 36.6+/-31.1 microg/ml in healthy controls. There were no significant differences between the patient and the control groups. CONCLUSIONS: We conclude that neither senile cataract nor POAG has any effect on the PLA2 content of tears.
Authors: Heikki Peuravuori; Osmo Kari; Sirje Peltonen; Valtteri V Aho; Jukka M Saari; Yrjö Collan; Marko Määttä; K Matti Saari Journal: Graefes Arch Clin Exp Ophthalmol Date: 2004-06-26 Impact factor: 3.117
Authors: Heikki Peuravuori; Valtteri V Aho; Heikki J Aho; Yrjö Collan; K Matti Saari Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-07-26 Impact factor: 3.117
Authors: Valtteri V Aho; Ville Paavilainen; Timo J Nevalainen; Heikki Peuravuori; K Matti Saari Journal: Graefes Arch Clin Exp Ophthalmol Date: 2003-01-25 Impact factor: 3.117